Category Archives: Angiex

Please join us! “Fireside chat” webinar tomorrow with Angiex founders

Posted by on October 29, 2024 3 comments

Dear readers,

Please join me Wednesday at 4 pm Eastern with famed scientist, angiogenesis expert, discoverer of VEGF, and Angiex co-founder Dr. Harold Dvorak in an online Fireside Chat.

We’ll discuss Hal’s pathbreaking work in angiogenesis; the efforts of Hal and his collaborators to develop a universal therapy for all solid cancers by attacking the tumor vasculature; and the prospects for achieving such a universal therapy through antibody-drug conjugate therapies directed against the protein TM4SF1.

We’ll look at the process of discovering TM4SF1’s amazing biology and building Angiex; and the state of Angiex’s lead drug AGX101, now showing promising early results in Phase 1 clinical trials for all solid cancers.

Please join us for a fascinating discussion of science, entrepreneurship, and the effort to fulfill Angiex’s vision that “No One Should Die of Cancer!”

Link: https://www.linkedin.com/events/angiex-inc-livewebinar7254915501640892416/

Angiex’s Upcoming Mission on the International Space Station

Posted by on June 26, 2018 26 comments

I think most of you know that the reason we haven’t been posting much the last three years is that Shou-Ching and I launched a biotech company, Angiex, in 2015 with the goal of creating a breakthrough cancer therapy.

Our drug is close to being finalized, and it is performing remarkably well. We have effectively regressed every tumor we’ve tested in rodents. There is good therapeutic margin in both mice and rats, and the drug is well tolerated in monkeys. There’s every reason to be optimistic it will do well in humans. There’s also reason to believe it will effectively treat the most malignant cancers, such as pancreatic cancer and liver cancer. The more aggressive the cancer, the better our drug works.

In the early days of the company, we applied to do an experiment in the US National Laboratory of the International Space Station, and were fortunate to receive funding for the experiment from Boeing and the Center for Advancement of Science in Space (CASIS) via the MassChallenge accelerator. We’re pleased to have received terrific support in developing the experiment from CASIS and BioServe Space Technologies. It’s now show time — the experiment is scheduled to launch this Friday, June 29, on SpaceX CRS-15.

CASIS came to our laboratory at LabCentral in Cambridge, Massachusetts, and made a very nice video explaining our experiment and some background about Angiex. We’re excited to share this glimpse at Angiex’s work. Enjoy!






Angiex on Television

Posted by on August 16, 2016 17 comments

If you’ve been wondering why there have been few blog posts over the last 18 months, it’s because Shou-Ching and I have been launching a biotech company, Angiex. Last week I got to speak about Angiex on the evening business program of New England Cable News, which is featuring participants in MassChallenge, “the most startup-friendly accelerator on the planet”: